Vimarsana
Biggest News Aggregation in the World

Page 2 - Subgroup Analysis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Subgroup Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Subgroup Analysis Today - Breaking & Trending Today

International Stroke Conference 2024 to Present High-Profile Late-Breaking Science - Vimarsana News

International Stroke Conference 2024 to Present High-Profile Late-Breaking Science

The International Stroke Conference 2024 will be held Feb. 7-9 in Phoenix, Arizona. According to program planners with the American Stroke Association, a division of the American Heart Association, findings from late-breaking science will include multiple high profile randomized clinical trials like RESILIENT-Extend, EMBOLISE, STEM, ZODIAC, among many others.

Advancements in Squamous NSCLC Treatment: Subgroup Analysis from EMPOWER-Lung Trials - Vimarsana News

Advancements in Squamous NSCLC Treatment: Subgroup Analysis from EMPOWER-Lung Trials

Eduardo Santos, MD, FACP, FCCP, delves into advancements in the treatment of squamous NSCLC, emphasizing crucial insights from the EMPOWER-Lung01 and EMPOWER-Lung03 subgroup analysis.

Florida Cancer Specialists & Research Institute Contributing to Cutting-Edge Advancements in Hematology Science - Vimarsana News

Florida Cancer Specialists & Research Institute Contributing to Cutting-Edge Advancements in Hematology Science

/PRNewswire/ -- Research conducted at Florida Cancer Specialists & Research Institute, LLC (FCS) was presented in the cutting-edge advancements being shared at...

Analyses of Kite's Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas -December 11, 2023 at 09:01 pm EST - Vimarsana News

Analyses of Kite's Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas -December 11, 2023 at 09:01 pm EST

– ZUMA-1 Post-Hoc Analysis Shows Five-Year Lymphoma-Related Event-Free Survival in a Substantial Proportion of Patients with Refractory Large B-cell Lymphoma – – Four-Year Follow-up from...

Eculizumab Biosimilar Comparable for Complement-Inhibitor Naive Patients with Paroxysmal Nocturnal Hemoglobinuria - Vimarsana News

Eculizumab Biosimilar Comparable for Complement-Inhibitor Naive Patients with Paroxysmal Nocturnal Hemoglobinuria

These results in the subgroup analysis, seen among individuals who were both identified as Asian and non-Asian, align with data published previously in the overall population.